Can you treat inflammation to lower heart risk? - Harvard Health
This story deserves to be shared
Send it to someone who'd care, or post it on your networks.
While a large study found that a drug to lower inflammation failed to prevent heart attacks and related risk, inflammation is still important in the development of coronary artery disease.
To continue reading this article, you must log in.
This article is an excerpt. To read the full content, visit the original source. Harvard Health
Related articles
How AI could help treat mental health - Wellcome Trust
Microplastics trigger inflammation linked to disease and death. Now scientists appear to have discovered why - The Spokesman-Review
Plain old water could be responsible for making plastics harmful to people, according to a new study that portends significant consequences for human health. The study, published Thursday in the prominent scientific journal Nature, found chemical reactions between water and six types of fossil fuel-based plastic created particles that damaged red blood cells and proteins in laboratory tests.
Popular sports supplement may help shield the brain from damage linked to gut inflammation - Medical Xpress
Creatine showed protective effects against brain inflammation triggered by chronic ulcerative colitis. The gut-brain axis is a two-way biochemical hotline, with messages zipping back and forth all day long. When the gut is chronically inflamed, inflammatory signals travel through the body to the brain and trigger neuroinflammation. The hippocampus, which governs memory, learning and mood, is especially vulnerable, so its disruption can affect how you think, remember and feel.
Bioengineer.org | Viral blips during HIV therapy are common and rarely signal treatment failure, Swedish study finds - European AIDS Treatment Group
Bioengineer.org news storyFor people living with HIV, modern antiretroviral therapy can suppress the virus to levels below what standard laboratory tests can detect. Yet some patients on long-term treatment experience a curious phenomenon: a single test result showing a small, transient amount of virus in the blood, followed by an immediate return to undetectable levels. These events, known as viral blips, have puzzled clinicians and researchers for years, raising questions about whether they represent harmless statistical noise, brief bursts of viral production from hidden reservoirs, or early warnings of impending treatment failure. A new nationwide Swedish study, published in BMC Infectious Diseases, offers one of the most comprehensive answers to date. Drawing on the Swedish national InfCareHIV cohort, researchers analyzed data from 4,210 treatment-naïve adults who began antiretroviral therapy from 1 January 2007 onward, with follow-up data extracted through 30 September 2020. The median observation time was 5.5 years, with some individuals followed for as long as 13.7 years.
0 comments
No comments yet. Be the first to share your thoughts!